Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety Study of Abatacept to Treat Refractory Sarcoidosis
NCT00739960 · University of Chicago · PHASE2 · terminated · last registry update 2020-03-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding has been pulled” | – | Registry record, University of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-05Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT02592798)
- 2021-02-26Also stopped (terminated): Bristol-Myers Squibb, BMS-188667 + Mycophenolate mofetil (NCT01714817)
- 2021-01-26Results posted on the registry: Andrew B Adams, Belatacept + Calcineurin inhibitor therapy (NCT01921218)
- 2021-01-07Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT03714022)
- 2021-01-05Results posted on the registry: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT01820572)
- 2020-12-31Phase 3 first posted: University of Alabama at Birmingham, targeted synthetic DMARD class + non-TNFi-biologic class (NCT04692493)
- 2020-12-01Also stopped (terminated): Medical University of Graz, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) (NCT01602302)
- 2020-11-25Results posted on the registry: Oklahoma Medical Research Foundation, Abatacept (NCT02270957)
- 2020-11-16Also stopped (withdrawn): University of California, Los Angeles, Abatacept + Placebo (NCT02053727)
- 2020-10-30Phase 3 first posted: University of Erlangen-Nürnberg Medical School, Prednisolone + Sulfasalazine (NCT04610476)
- 2020-10-20Phase 3 first posted: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2020-10-01Results posted on the registry: Dr. Larry W. Moreland, TNF Antagonist (enbrel, humire, remicade, cimzia, symponi) + Abatacept (NCT02353780)
- 2020-10-01Also stopped (terminated): Dr. Larry W. Moreland, TNF Antagonist (enbrel, humire, remicade, cimzia, symponi) + Abatacept (NCT02353780)
- 2020-09-18Results posted on the registry: Emory University, Belatacept (NCT02560558)
- 2020-09-03Results posted on the registry: Bristol-Myers Squibb, Abatacept + Adalimumab (NCT02557100)
- 2020-07-20Also stopped (withdrawn): Beth Israel Deaconess Medical Center, Abatacept (NCT04477642)
- 2020-07-17Phase 3 first posted: University of Pennsylvania, Abatacept + Placebo (NCT04474847)
- 2020-06-17Results posted on the registry: Boston Children's Hospital, Abatacept + placebo (NCT01743131)
- 2020-06-04Results posted on the registry: AbbVie, Abatacept + Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion) (NCT03086343)
- 2020-03-30Results posted on the registry: Christopher Bowlus, MD, abatacept (NCT02078882)
- 2020-01-30Results posted on the registry: Allan D Kirk, MD, PhD, Belatacept + Sirolimus (NCT00565773)
- 2020-01-02Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT02915159)
- 2019-11-22Also stopped (terminated): Johns Hopkins University, Abatacept Injection (NCT03059888)
- 2019-09-10Results posted on the registry: Columbia University, Belatacept + Tacrolimus (NCT02152345)
- 2019-07-10Phase 3 first posted: Nantes University Hospital, Belatacept 250 Milligram Intravenous Powder for Solution (NCT04013620)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision